Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection
International Journal of Molecular Medicine · 2025
DOI: 10.3892/ijmm.2025.5647 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2025. Verfasst von Rui Chao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Osteoclasts, Kelch-Like ECH-Associated Protein 1, Osteolysis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Inflammatory bone resorption, especially bone loss caused by the abnormal activation of osteoclasts (OCs), has become an increasing health concern. As a natural anti‑inflammatory compound, cynarin has shown potential in the treatment of various inflammatory diseases; however, its role in inflammatory bone resorption remains to be investigated. The present study aimed to explore the therapeutic potential of cynarin in inflammatory bone resorption by focusing on its regulatory effects on OC differentiation, inflammatory responses and related signalling pathways. Our results showed that cynarin significantly inhibited bone resorption, reduced tartrate‑resistant acid phosphatase activity, and downregulated key OC differentiation markers (Atp6v0d2, Nfatc1, Dcstamp and Ctsk). RNA sequencing and western blot analyses revealed that cynarin inhibited mitogen‑activated protein kinase (MAPK) pathway activation, and that the MAPK‑specific activator anisomycin reversed this inhibitory effect. In addition, cynarin alleviated the inflammatory response by reducing reactive oxygen species levels and inhibiting the expression of inflammatory cytokines. More importantly, cynarin activated Nrf2 and enhanced the expression of antioxidant genes (Hmox and Cat). Micro‑computed tomography analysis revealed that cynarin significantly enhanced the bone structure in mice, as indicated by increased bone volume and trabecular number, and trabecular thickness. Histological analysis confirmed that cynarin inhibited the expression of OC markers (tartrate‑resistant acid phosphatase, receptor activator of nuclear factor κB and cathepsin K) and inflammatory factors (tumor necrosis factor‑alpha and inducible nitric oxide synthase), while promoting osteogenic markers (osteocalcin and RUNX2). Finally, cynarin‑treated mice showed enhanced Nrf2 nuclear translocation and inhibition of MAPK signalling. These findings revealed the multiple roles of cynarin in the treatment of inflammatory osteolysis and provided insights into its potential therapeutic mechanisms and targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
- Department of Stomatology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China.
Zitieren
APA
Chao, R., Wang, Y., Liu, Z., Wan, T., Mao, Y., Xie, X., Sun, L., Xu, W., Chen, X., & Zhang, S. (2025). Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2025.5647
Vancouver
Chao R, Wang Y, Liu Z, Wan T, Mao Y, Xie X, et al. Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection. International Journal of Molecular Medicine. 2025. doi:10.3892/ijmm.2025.5647
BibTeX
@article{Chao2025,
author = {Chao, Rui and Wang, Yexin and Liu, Zhan and Wan, Tianhao and Mao, Yi and Xie, Xinru and Sun, Lei and Xu, Weifeng and Chen, Xuzhuo and Zhang, Shanyong},
title = {Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection},
journal = {International Journal of Molecular Medicine},
year = {2025},
doi = {10.3892/ijmm.2025.5647}
}
EUVIMED